BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 18523022)

  • 1. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection.
    King CL; Michon P; Shakri AR; Marcotty A; Stanisic D; Zimmerman PA; Cole-Tobian JL; Mueller I; Chitnis CE
    Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8363-8. PubMed ID: 18523022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children.
    Cole-Tobian JL; Michon P; Biasor M; Richards JS; Beeson JG; Mueller I; King CL
    Infect Immun; 2009 Sep; 77(9):4009-17. PubMed ID: 19564376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein.
    Grimberg BT; Udomsangpetch R; Xainli J; McHenry A; Panichakul T; Sattabongkot J; Cui L; Bockarie M; Chitnis C; Adams J; Zimmerman PA; King CL
    PLoS Med; 2007 Dec; 4(12):e337. PubMed ID: 18092885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses to Plasmodium vivax Duffy binding and Erythrocyte binding proteins predict risk of infection and are associated with protection from clinical Malaria.
    He WQ; Shakri AR; Bhardwaj R; França CT; Stanisic DI; Healer J; Kiniboro B; Robinson LJ; Guillotte-Blisnick M; Huon C; Siba P; Cowman A; King CL; Tham WH; Chitnis CE; Mueller I
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0006987. PubMed ID: 30768655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians.
    Nicolete VC; Frischmann S; Barbosa S; King CL; Ferreira MU
    J Infect Dis; 2016 Nov; 214(10):1539-1546. PubMed ID: 27578850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting a Reticulocyte Binding Protein and Duffy Binding Protein to Inhibit Reticulocyte Invasion by Plasmodium vivax.
    Gupta S; Singh S; Popovici J; Roesch C; Shakri AR; Guillotte-Blisnick M; Huon C; Menard D; Chitnis CE
    Sci Rep; 2018 Jul; 8(1):10511. PubMed ID: 30002416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody.
    Rawlinson TA; Barber NM; Mohring F; Cho JS; Kosaisavee V; Gérard SF; Alanine DGW; Labbé GM; Elias SC; Silk SE; Quinkert D; Jin J; Marshall JM; Payne RO; Minassian AM; Russell B; Rénia L; Nosten FH; Moon RW; Higgins MK; Draper SJ
    Nat Microbiol; 2019 Sep; 4(9):1497-1507. PubMed ID: 31133755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II.
    Wongkidakarn S; McHenry AM; Sattabongkot J; Adams JH; Chootong P
    PLoS One; 2016; 11(5):e0154577. PubMed ID: 27145131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission.
    Zakeri S; Babaeekhou L; Mehrizi AA; Abbasi M; Djadid ND
    Am J Trop Med Hyg; 2011 Jun; 84(6):944-50. PubMed ID: 21633032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
    Mertens JE; Rigby CA; Bardelli M; Quinkert D; Hou MM; Diouf A; Silk SE; Chitnis CE; Minassian AM; Moon RW; Long CA; Draper SJ; Miura K
    Vaccine; 2024 Jun; 42(16):3621-3629. PubMed ID: 38704253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain.
    George MT; Schloegel JL; Ntumngia FB; Barnes SJ; King CL; Casey JL; Foley M; Adams JH
    mSphere; 2019 May; 4(3):. PubMed ID: 31092602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.
    Ntumngia FB; Schloegel J; McHenry AM; Barnes SJ; George MT; Kennedy S; Adams JH
    Vaccine; 2013 Sep; 31(40):4382-8. PubMed ID: 23916294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein (PvDBP-II) equally block erythrocyte binding of homologous and heterologous expressed PvDBP-II on the surface of COS-7 cells.
    Valizadeh V; Zakeri S; Mehrizi AA; Mirkazemi S; Djadid ND
    Med Microbiol Immunol; 2016 Feb; 205(1):85-95. PubMed ID: 26243337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC).
    Maestre A; Muskus C; Duque V; Agudelo O; Liu P; Takagi A; Ntumngia FB; Adams JH; Sim KL; Hoffman SL; Corradin G; Velez ID; Wang R
    PLoS One; 2010 Jul; 5(7):e11437. PubMed ID: 20664684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II immunogen: Strain-specific and strain-transcending immune responses over a nine-year period.
    Medeiros CMP; Moreira EUM; Pires CV; Torres LM; Guimarães LFF; Alves JRS; Lima BAS; Fontes CJF; Costa HL; Brito CFA; Sousa TN; Ntumngia FB; Adams JH; Kano FS; Carvalho LH
    PLoS One; 2020; 15(5):e0232786. PubMed ID: 32379804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-allele specific antibody responses to genetically distinct variant forms of Plasmodium vivax Duffy binding protein (PvDBP-II) in Iranians exposed to seasonal malaria transmission.
    Valizadeh V; Zakeri S; Mehrizi AA; Djadid ND
    Acta Trop; 2014 Aug; 136():89-100. PubMed ID: 24704284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon.
    de Sousa TN; Kano FS; de Brito CF; Carvalho LH
    Mem Inst Oswaldo Cruz; 2014 Aug; 109(5):608-17. PubMed ID: 25185002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-Species Immune Recognition Between Plasmodium vivax Duffy Binding Protein Antibodies and the Plasmodium falciparum Surface Antigen VAR2CSA.
    Gnidehou S; Mitran CJ; Arango E; Banman S; Mena A; Medawar E; Lima BAS; Doritchamou J; Rajwani J; Jin A; Gavina K; Ntumngia F; Duffy P; Narum D; Ndam NT; Nielsen MA; Salanti A; Kano FS; Carvalho LH; Adams JH; Maestre A; Good MF; Yanow SK
    J Infect Dis; 2019 Jan; 219(1):110-120. PubMed ID: 30534974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity.
    Popovici J; Roesch C; Carias LL; Khim N; Kim S; Vantaux A; Mueller I; Chitnis CE; King CL; Witkowski B
    Nat Commun; 2020 Feb; 11(1):953. PubMed ID: 32075983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants.
    Kano FS; Souza-Silva FA; Torres LM; Lima BA; Sousa TN; Alves JR; Rocha RS; Fontes CJ; Sanchez BA; Adams JH; Brito CF; Pires DE; Ascher DB; Sell AM; Carvalho LH
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005177. PubMed ID: 27959918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.